Cystic fibrosis newborn screening: outcome of infants with normal sweat tests
- 1 August 2018
- journal article
- research article
- Published by BMJ in Archives of Disease in Childhood
- Vol. 103 (8) , 753-756
Abstract
Newborn babies positively screened for cystic fibrosis (CF) (high serum immunoreactive trypsin (IRT) with DNA analysis) are referred for a diagnostic sweat test, which may be normal (sweat chloride <30 mmol/L). Unless two gene mutations are identified during Newborn screening (NBS), the babies are discharged from follow-up. We wished to check that none had subsequently developed symptoms suggestive of CF. We retrospectively reviewed patient notes and contacted general practitioners of all babies with a negative sweat test, conducted in one of the four paediatric specialist CF centres in London, over the first 6 years of screening in South East England. Of 511 babies referred, 95 (19%) had a normal sweat test. Five (5%) had CF diagnosed genetically, two of them on extended genome sequencing after clinical suspicion. Eleven (12%) were designated as CF screen positive inconclusive diagnosis (CFSPID); one of the five CF children was originally designated as CFSPID. Seventy-nine (83%) were assumed to be false-positive cases and discharged; follow-up data were available for 51/79 (65%); 32/51 (63%) had no health issues, 19/51 (37%) had other significant non-CF pathology. These results are reassuring in that within the limitations of those lost to follow-up, CF symptoms have not emerged in the discharged children. The high non-CF morbidity in these children may relate to known causes of high IRT at birth. Clinicians need to be aware that a child can have CF despite a normal sweat test following NBS, and if symptoms suggest the diagnosis, further testing, including extended genome sequencing, is required.Keywords
This publication has 12 references indexed in Scilit:
- Sources of Variation in Sweat Chloride Measurements in Cystic FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2016
- Cystic fibrosis screen positive, inconclusive diagnosisCurrent Opinion in Pulmonary Medicine, 2016
- Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID): A new designation and management recommendations for infants with an inconclusive diagnosis following newborn screeningJournal of Cystic Fibrosis, 2015
- Screening for cystic fibrosis in New York State: considerations for algorithm improvementsEuropean Journal of Pediatrics, 2015
- Diagnosis of cystic fibrosis in London and South East England before and after the introduction of newborn screeningArchives of Disease in Childhood, 2013
- Immunoreactive trypsinogen (IRT) as a biomarker for cystic fibrosis: Challenges in newborn dried blood spot screeningMolecular Genetics and Metabolism, 2012
- European best practice guidelines for cystic fibrosis neonatal screeningJournal of Cystic Fibrosis, 2009
- Newborn screening for cystic fibrosis: evidence for benefitArchives of Disease in Childhood, 2008
- Markedly elevated neonatal immunoreactive trypsinogen levels in the absence of cystic fibrosis gene mutations is not an indication for further testingArchives of Disease in Childhood, 2006
- Sweat‐testing: A review of current technical requirementsPediatric Pulmonology, 2005